Adverum Biotechnologies, Inc. (ADVM) Sees A 28.08% Move Today And Traders Have A Way To Play It

Adverum Biotechnologies, Inc. (NASDAQ:ADVM) is in the list of top stocks to avoid today as the company shares are trading 28.08% or 3.37 points down from last closing price of $12, reaching $8.63 at last check. The ADVM share price has dropped in 2 of the last 5 days and is up 8.5% over the past week. It will be exciting to see whether the stock manages to continue decreasing or take a minor break for the next few days. The move came on solid volume too with far more shares changing hands than in a normal session. Trading activity as of this writing strengthened by 9,017,624 shares, and in total 10.935 million shares valued at $94.373 million were seen changing hands compared with 1.918 million shares valued at $23.014 million recorded at the previous session. You should take into consideration that a greater volume on lower prices causes the situation where nobody wants to continue with their long position and wants to exit from the ADVM stock.

Adverum Biotechnologies, Inc. (ADVM) shares have notched a 3-month gain of about 8.5%, but has still advanced 280.95% year to date. By comparison, the stock added 79.1% over the past 12 months, while it jumped 4.53% over the 1 month. The company’s market cap is around $768.36M, with its short interest ratio standing at 8%.

In the current trading session for ADVM, the stock witnessed two major price actions, it rose to a high of $9 and was down as much as $8.67 at one point. The high recorded is very low when compared to their 52-week high which is $2.62. The 52-week high is now at -47.57 distance from current price. Their recent low of $16.38 represents a 227.86% recovery. This data is quite important for investors who look to benefit from the recent rise of the company’s stock. The price target currently for ADVM is $9.75, this is below the recent high that the stock attained. Taking a look at the overall sentimental views of financial analysts, the trading pattern of this stock recently is very clear.

The stock of Adverum Biotechnologies, Inc. earned $-1.05 per share in the trailing 12 months and has a P/E ratio of -8.22. You can compare it with that of similar companies in its industry to get a sense of whether the stock you’re looking to purchase is overvalued or undervalued. Its current price to earnings ratio is lower than the ones recorded by the industry which is 30.46 and lower compared to the sector’s average of 30.52. When the P/E ratio is low let’s say below 1.0, then the stock price is considered a good value. ADVM also has P/S multiple of 613.98. This is greater versus the 12 month P/S ratios of other companies in the same indutry. The peer average price to sales ratio is 2.34x.

The company recorded an interesting insider purchase transaction by the Director on May 06, 2019. A Securities and Exchanges Commission filings show that James Paul Scopa bought a total of 20,000 ADVM shares that day for a sum of around $134,200. Adverum Biotechnologies, Inc. (ADVM) insiders have acquired no shares in the stock within the past three months. In total, individual insiders traded no shares in the business, which makes up 0% of 20,000 shares that were traded over a year. In the past 12 months, insiders have purchased 20,000 shares while the seller parted with shares.

ADVM‘s last price was up 14.51% as compared to the average trading price of 50 days recorded at $7.54 while enlarging the period to 200 trading days, the average closing price was $12.73. At present, there are 64.03 million in the total number of common shares owned by the public and among those 56.21 million shares have been available to trade. The percentage of shares being held by the company management was 11.22% while institutions stake was 85.5%. The company has generated negative returns on equity over the last 12 months (-33.8%). It managed to keep its gross profit margin at 0% over the past 12 months.

When assessing the full upside of the ADVM stock, there is another set of technicals that should be looked into and considered. Its -25.63% decline from moving average of $11.6 has brought about a negative sentiment when calculated over the last 20 days. The market has allocated a beta of 2.58 to the stock. With the beta been greater than one, this implies that the company shares are theoretically more volatile than the market, something that the traders definitely are keeping an eye on.

Most of the analysts surveyed by Thomson/First Call think quite highly of Adverum Biotechnologies, Inc. — 2 analysts rate the stock as a buy with another 0 rating it strong buy. There are 4 analysts who maintain a hold rating for the stock, with 0 giving it a sell rating. Analysts arrived at a 12-month price target of $9.5 on shares of Adverum Biotechnologies, Inc. (NASDAQ:ADVM), which corresponds to 7.95% upside potential than its current market price of $8.63 and implies potential despite the recent drop in the price. However, their current target price has climbed from $8.125 a month ago and is up handily from the consensus target of $7.875 a quarter ago.

In the last five years, the EPS of the company has been roughly -36.8%. Though the percentage looks disappointing, extra headwinds are emerging as looking out over a next 5-year period, with analysts estimating that their earnings will decrease annually by 0%. The revenue of the company has risen at an average annualized rate of about 27.4 over the last five years. The company recently recorded a drop of 0%, but this figure is rather unattractive.

Let’s briefly check the hedge fund interest towards ADVM stock. Orbimed Advisors LLC added position in the company after it grew 57.7% or 1,242,993 shares of its common stock. The hedge fund now owns 1,960,200 shares worth $16,916,526, SEC documents show. Primecap Management Co. CA shored up assets in the stock as 1051506 shares have been purchased, increasing its stake by 2.9% to 1,082,000 shares which are currently valued at $9,337,660. In addition, UBS Group AG recently reported that it now owns 3,138,539 shares making a total of $27,085,592 based on the recent price. This refelects a change of 52.1% in their ownership.